Trial Profile
Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Fulacimstat (Primary)
- Indications Kidney disorders; Left ventricular dysfunction; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bayer
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2018 Planned End Date changed from 19 Dec 2018 to 11 Feb 2019.